Results 161 to 170 of about 59,485 (323)

Innovative Drug Delivery Systems for the Treatment of Glaucoma

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 2, June 2026.
This review aims to provide a comprehensive overview of current topical drug delivery strategies for ocular hypotensive agents in glaucoma therapy. Additionally, it discusses the potential impact of emerging nanotechnological and biomaterial‐based systems in shaping the future of ophthalmic drug delivery, with an emphasis on enhancing efficacy, safety,
Jing Chu   +9 more
wiley   +1 more source

Anterior chamber flare and central macular thickness after trabeculectomy versus after phacoemulsification

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 402-409, June 2026.
Abstract Purpose To compare the inflammatory response in the eye after trabeculectomy to after phacoemulsification, focusing on anterior chamber flare (AC flare) and central macular thickness (CMT). Methods Data from 436 participants in two randomized controlled trials were analysed.
Yasmeen Ahmed   +5 more
wiley   +1 more source

Vitreoretinal complications and surgical outcomes in patients with X‐linked retinoschisis

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 410-422, June 2026.
Abstract Purpose X‐linked retinoschisis (XLRS) is an inherited vitreoretinal disorder characterized by macular retinoschisis. In a subgroup of patients, peripheral retinoschisis can occur, potentially leading to complications such as vitreous haemorrhage (VH) and retinal detachment (RD).
Jonathan Hensman   +11 more
wiley   +1 more source

Tuberculous Endophthalmitis With Phthisis Bulbi: A Diagnostic Delay Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Tuberculous endophthalmitis should be prioritized in differential diagnosis for unexplained endophthalmitis in TB‐endemic regions; early systemic evaluation, timely pars plana vitrectomy, and adjunctive corticosteroids are crucial to prevent phthisis bulbi, though evidence for some interventions remains limited.
Yanchen Chen   +4 more
wiley   +1 more source

Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT A patient with advanced bladder cancer received antitumor therapy consisting of gemcitabine on days 1 and 8 combined with cisplatin and treliprimab on day 1. Severe periorbital hyperpigmentation occurred 30 min after gemcitabine infusion on day 8. Symmetrical diffuse hyperpigmentation of a dark brown hue with indistinct borders appeared around
Li Juan, Chen Weiping
wiley   +1 more source

Prevalence and Associated Factors of Self‐Reported Myopia Among Undergraduate Students in the Northern Region of Bangladesh: A Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Myopia is an increasingly important public health concern worldwide, particularly among young adults. While previous research has applied machine learning techniques to identify myopia‐related risk factors, evidence based on traditional statistical models using the same datasets remains limited. This study aimed to estimate
Tajin Ahmed Jisa   +6 more
wiley   +1 more source

Comparative Study of Accommodative Function and Binocular Vision in Patients With Primary Angle‐Closure Disease

open access: yesThe Kaohsiung Journal of Medical Sciences, Volume 42, Issue 5, May 2026.
ABSTRACT The age‐related decline in accommodative function after the age of 50 years corresponds with an increasing incidence of primary angle‐closure disease (PACD); however, the interaction between this decline and PACD remains unexamined. Additionally, refractive error‐accommodation associations in elderly individuals, which are critical for PACD ...
Feng‐Rui Yang   +6 more
wiley   +1 more source

Role of toric intraocular lenses in the correction of keratoconic eyes with cataract. [PDF]

open access: yesJ Cataract Refract Surg
Francis SM   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy